PMG
TEVA icon

ProVise Management Group’s Teva Pharmaceuticals TEVA Stock Holding History

ProVise Management Group’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-4,272
Closed -$224K – 320
2014
Q2 		$224K Hold
4,272
– – 0.05% 282
2014
Q1 		$226K Buy
+4,272
New +$197K 0.05% 272

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ProVise Management Group's TEVA Position: Q3 2014 in Review

ProVise Management Group sold out of Teva Pharmaceuticals (TEVA) in Q3 2014, closing a stake of 4,272 shares — an estimated $224K sold.

ProVise Management Group first reported a position in TEVA in Q1 2014 and held it in 2 quarters. The position peaked at $226K in Q1 2014. 772 funds tracked by Wall St. Rank hold TEVA as of Q3 2014.

  • ProVise Management Group reported no remaining Teva Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • ProVise Management Group sold 4,272 Teva Pharmaceuticals shares in Q3 2014, an estimated $224K.
  • ProVise Management Group first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • ProVise Management Group's Teva Pharmaceuticals position peaked at $226K in Q1 2014.
  • 772 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2014.

Based on ProVise Management Group's 13F filing for Q3 2014, filed 10 Nov 2014.